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Simple Summary: The study objective was to determine if an SNP (single nucleotide polymorphism)-
based immune multi-gene panel has the ability to predict adjuvant BCG (Bacillus Calmette–Guérin)
immunotherapy responsiveness post-tumor resection in AJCC (American Joint Committee on Cancer)
stages III and IV metastatic melanoma patients. A pilot study followed by further verification
and control melanoma patient cohorts involving three phase III multicenter clinical trials was
used to verify if an immune gene SNP panel could identify if adjuvant BCG therapy correlates
with disease outcomes. We found a specific immune gene SNP panel that could identify which
patients would respond to adjuvant BCG immunotherapy, but it was not applicable in the control
non-immunotherapy treated patients. These studies provide evidence that SNP immune-gene
assessment has utility in predicting melanoma patient’s immunotherapy responses to adjuvant
BCG immunotherapy.
Abstract: Adjuvant immunotherapy in melanoma patients improves clinical outcomes. However,
success is unpredictable due to inherited heterogeneity of immune responses. Inherent immune
genes associated with single nucleotide polymorphisms (SNPs) may influence anti-tumor immune
responses. We assessed the predictive ability of 26 immune-gene SNPs genomic panels for a clinical
response to adjuvant BCG (Bacillus Calmette-Guérin) immunotherapy, using melanoma patient
cohorts derived from three phase III multicenter clinical trials: AJCC (American Joint Committee
on Cancer) stage IV patients given adjuvant BCG (pilot cohort; n = 92), AJCC stage III patients given
adjuvant BCG (verification cohort; n = 269), and AJCC stage III patients that are sentinel lymph
node (SLN) positive receiving no immunotherapy (control cohort; n = 80). The SNP panel analysis
demonstrated that the responder patient group had an improved disease-free survival (DFS) (hazard
ratio [HR] 1.84, 95% CI 1.09–3.13, p = 0.021) in the pilot cohort. In the verification cohort, an improved
overall survival (OS) (HR 1.67, 95% CI 1.07–2.67, p = 0.025) was observed. No significant differences
of SNPs were observed in DFS or OS in the control patient cohort. This study demonstrates that
SNP immune genes can be utilized as a predictive tool for identifying melanoma patients that are
inherently responsive to BCG and potentially other immunotherapies in the future.
Keywords: SNP; Bacille Calmette–Guérin; metastatic melanoma; cancer immunology; adjuvant
immunotherapy; innate immunity
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1. Introduction
Melanoma is an antigenic cancer, whereby activated host anti-tumor immunity has
been shown to control tumor progression. Adjuvant immunotherapies that have been used
in melanoma clinical trials are: Interferon-α-2b (IFN-α-2b), Interleukin (IL)-2, melanoma
cell vaccines, BCG (Bacillus Calmette-Guérin), and immune checkpoint inhibitors (ICI)
immunotherapy in post-surgical, disease-free AJCC (American Joint Committee on Cancer)
stage III and IV patients [1–4]. Newer immunotherapies using monoclonal antibodies,
such as ICIs, which target against CTLA-4, PD-1, or PD-L1 [5–7], have improved overall
survival time when used as both adjuvant and neo-adjuvant therapies in AJCC stage III/IV
melanoma patients [8–11]. ICI agents, nivolumab and pembrolizumab therapies, which
are less toxic and have better recurrence-free survival rates, are the most effective and
current standard of care for the treatment of melanoma patients [1]. However, predicting
which patients will respond to these different immunotherapies still remains unknown.
In order to improve disease outcomes and reduce unnecessary treatments, personalized
therapy for melanoma patients may be needed using an evidence based approach of these
patients’ inherited immune status [12]. To date, there are no efficient immune indicators
or biomarker tests available to use prior to the initiation of treatment to prospectively
identify potential responders to adjuvant immunotherapy. To improve the efficacy of
immunotherapies, we need to identify patients that will respond prior to treatment. Our
approach to address this issue was to assess retrospectively our multicenter adjuvant
clinical trials with long-term clinical follow-up.
BCG, an attenuated live strain of Mycobacterium bovis, is an immune-modulating
agent used in the treatment of melanoma and bladder cancer patients to train innate
immunity [13–15]. Several clinical trials have assessed BCG as a post-surgical adjuvant
treatment in both early- and late-stage metastatic melanoma [3,16–19]. Moreover, a recent
phase-I/II clinical trial study (NCT01729663) for the CSF470 allogeneic cell vaccine (derived
from four cutaneous melanoma cell lines) plus BCG and GM-CSF as adjuvants, revealed
an enhanced immune response and a longer distant metastasis-free survival with lower
toxicity [20,21]. Past evidence shows that the anti-tumor immunity of BCG can be enhanced
through training of the innate immune system [14]. Improved outcomes with BCG have
been observed in individual melanoma patients. However, it still remains unknown why
some patients respond to treatment while others do not [22,23].
With modern day immunotherapies, it is important to identify how a patient’s immune
system will respond before treatment. Single nucleotide polymorphisms (SNPs), which
are single base pair alterations located in the human genome, can affect specific immune
genes activity particularly those involved in response to cancer and other diseases, thereby
accounting for patients’ variable responses to immunotherapy [24,25]. SNPs occur in
coding and non-coding regions and can cause changes in biological functions through the
expression or modification of key immune genes protein expression and their respective
function. There are >5 million (https://ghr.nlm.nih.gov/primer/genomicresearch/snp)
SNPs in the human genome. The heterogeneity in patients’ immune responses is due to
their inherited genetic profiles. To determine the predictive value of immune SNP genes
to BCG immunotherapy in melanoma patients, we assessed three phase III multicenter
clinical trials involving melanoma AJCC stage III and IV patients who were rendered
disease free by surgery and then were monitored in long-term clinical follow-up. In two
of the multicenter clinical trials, patients were given BCG to activate their host innate
immunity post-surgery after rendered disease-free [16,17,26]. We hypothesized that SNPs
in specific immune-genes are related to BCG activation of the host immune response and
could predict the level of effectiveness of adjuvant BCG treatment in melanoma patients.
To test our hypothesis, we developed an immunologic panel of 26 SNPs that included
cytokines, chemokines, macrophage/monocyte activation markers, dendritic cells marker,
and toll-like receptors (TLRs) to assess their ability to predict patients’ responses to adjuvant
BCG immunotherapy post-surgery resection [16,17].
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Studies have shown that some patients respond more readily to BCG than others [27,28].
Individuals of Asian and European descent, who usually get BCG vaccinations at an early
stage in life, are known to have better immune responses to pathogens due to their trained
innate immunity after vaccination. In analogous pharmacogenetics studies, immune-
related gene SNPs may underlie differences in an individual’s responsiveness to certain
immune drugs [29,30]. In this study, we identified key immune related gene variants that




The study involved 441 metastatic melanoma patients.The pilot cohort consists of
stage IV BCG-treated patients (n = 92) from the JWCI Multicenter Malignant Melanoma
Active Immunotherapy Trial (MMAIT-IV) (Figure 1 CONSORT diagram; Table S1A).The
verification cohort has stage III BCG-treated patients (n = 269) from the MMAIT-III (Figure
2 CONSORT diagram; Table S1B), and the control cohort comprises stage III SLN positive
non-BCG and non-immunotherapy treated patients (n = 80) from the phase III Multicen-
ter Selective Lymphadenectomy Trial of JWCI (MSLT-I) (Figure 3 CONSORT diagram;
Table S1C). The clinicopathologic characteristics of the patients used in this study are
presented in Table S1A–C. In the MMAIT stage IV study group, there were 58 patients
(63%) with disease recurrence and 31 patients (34%) who expired. In the MMAIT stage III
study group, 124 patients (46%) with disease recurrence and 86 patients (32%) who expired.
In the MSLT-I stage III comparative study group, 39 patients (49%) had disease recurrence
and 30 patients (38%) expired. Patients in the trials were selected based on the availability
of PBLs and long-term clinical follow-up.
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Figure 1. CONSORT diagram of MMAIT-Stage IV patients from the phase III randomized double-blinded international 
multi-center trial. The flow diagram describing the MMAIT-IV (NCT00052156) trial, is shown. Selected patients (n = 92) 
from MMAIT-IV trial were used as a pilot study cohort. MMAIT = Malignant Melanoma Active Immunotherapy Trial; 
SLN = Sentinel Lymph Node; PBL = Peripheral Blood Leukocytes; SNP = Single Nucleotide Polymorphism. 
i re 1. CONSORT diagram of MAIT-Stage IV patients from the phase III randomized double-blinded inter -
tional multi-center trial. The flow diagram describing the MMAIT-IV (NCT00052156) trial, is shown. Selected patients
(n = 92) from MMAIT-IV trial were used as a pilot study cohort. MMAIT = Malignant Melanoma Active Immunotherapy
Trial; SLN = Sentinel Lymph Node; PBL = Peripheral Blood Leukocytes; SNP = Single Nucleotide Polymorphism.
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Figure 2. CONSORT diagram of MMAIT-Stage III patients from the phase III randomized double-blinded international 
multi-center trial. The flow diagram describing the MMAIT-III (NCT00052130) trial is shown. Selected 269 patients from 
MMAIT-III trial were used as a verification cohort. ECOG = Eastern Cooperative Oncology Group; MMAIT = Malignant 
Melanoma Active Immunotherapy Trial; SLN = Sentinel Lymph Node; PBL = Peripheral Blood Leukocytes; SNP = Single 
Nucleotide Polymorphism. 
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Figure 3. CONSORT diagram of MSLT-I Stage III patients from the phase III randomized double-blinded international 
multi-center trial. The flow diagram describing the MSLT-I (NCT00275496) trial, is shown. Selected 80 patients from 
MSLT-I trial were used as a control cohort. MSLT = Multicenter Selective Lymphadenectomy Trial; SLN = Sentinel Lymph 
Node; WEX = Wide Excision; SLNB = Sentinel Lymph Node Biopsy; CLND = Complete Lymph Node Dissection; PBL = 
Peripheral Blood Leukocytes; SNP = Single Nucleotide Polymorphism. Blood was taken pre-SLN surgery. 
2.2. Immune Gene SNP Selection 
In this study, immune-gene SNPs were characterized by a MassARRAY SNP geno-
typing and selected by going through the available literature. SNPs were selected on the 
basis of their relation to the host immune responses to BCG, tuberculosis (TB), and trained 
innate tumor immunity. As shown in Table 1, the SNPs that we selected were all previ-
ously reported to be important for host trained innate and BCG treatment adaptive im-
mune responses. The following are the list of genes with their respective SNP sites (in 
parenthesis): Inflammatory cytokines such as, TNF (rs1800629, rs361525), IL1β (rs1143627, 
rs1143634, rs16944), IL8 (rs4073), IL10 (rs1800896), IL12β (rs17860508), and IL23R 
(rs1343151). Chemokine receptor/chemokine: CCR5 (rs1799987) and CXCL12 (rs1801157). 
TLR such as TLR2 (rs4696480, rs5743708); macrophages/monocytes such as: NRAMP1 
(natural resistance-associated macrophage protein 1)/SLC11A1 (solute carrier protein 
11A1) (rs17215556, rs17235409, rs17235416, rs34448891, rs3731865). NRAMP1 is a mem-
brane-associated transporter of divalent metal ions associated with macrophages in BCG 
responses [31]. CD14 (rs2569190, rs2569193) is a monocyte/macrophage differentiation an-
tigen on the surface of myeloid lineage, such as monocytes, macrophages, and dendritic 
cells (DCs)[32]. CD18 (rs684, rs117989670), also known as β2 integrin subunit, is linked to 
monocyte hematopoiesis regulation [33]. Dendritic cells such as CD209 (Cluster of Differ-
entiation 209) is also known as DC-SIGN (Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin) (rs4804803). SP110 (rs3948464, rs1135791) is a nuclear 
body multiprotein complex and has been linked to Mycobacterium tuberculosis resistance 
[34]. BTNL2 (Butyrophilin Like 2) (rs2076530) is a protein coding gene and has been linked 
Figure 3. CONSORT diagram of MSLT-I Stage III patients from the phase III randomized double-blinded international
multi-center trial. The flow diagram describing the MSLT-I (NCT00275496) trial, is shown. Selected 80 patients from MSLT-I
trial were used as a control cohort. MSLT = Multicenter Selective Lymphadenectomy Trial; SLN = Sentinel Lymph Node;
WEX = Wide Excision; SLNB = Sentinel Lymph Node Biopsy; CLND = Complete Lymph Node Dissection; PBL = Peripheral
Blood Leukocytes; SNP = Single Nucleotide Polymorphism. Blood was taken pre-SLN surgery.
2.2. Immune Gene SNP Selection
In this study, immune-gene SNPs were characterized by a MassARRAY SNP geno-
typing and selected by going through the available literature. SNPs were selected on
the basis of their relation to the host immune responses to BCG, tuberculosis (TB), and
trained innate tumor immunity. As shown in Table 1, the SNPs that we selected were
all previously reported to be important for host trained innate and BCG treatment adap-
tive immune responses. The following are the list of genes with their respective SNP
sites (in parenthesis): Inflammatory cytokines such as, TNF (rs1800629, rs361525), IL1β
(rs1143627, rs1143634, rs16944), IL8 (rs4073), IL10 (rs1800896), IL12β (rs17860508), and
IL23R (rs1343151). Chemokine receptor/chemokine: CCR5 (rs1799987) and CXCL12
(rs1801157). TLR such as TLR2 (rs4696480, rs5743708); macrophages/monocytes such
as: NRAMP1 (natural resistance-associated macrophage protein 1)/SLC11A1 (solute car-
rier protein 11A1) (rs17215556, rs17235409, rs17235416, rs34448891, rs3731865). NRAMP1
is a membrane-associated transporter of divalent metal ions associated with macrophages
in BCG responses [31]. CD14 (rs2569190, rs2569193) is a monocyte/macrophage differen-
tiation antigen on the surface of myeloid lineage, such as monocytes, macrophages, and
dendritic cells (DCs) [32]. CD18 (rs684, rs117989670), also known as β2 integrin subunit, is
linked to monocyte hematopoiesis regulation [33]. Dendritic cells such as CD209 (Cluster
of Differentiation 209) is also known as DC-SIGN (Dendritic Cell-Specific Intercellular
adhesion molecule-3-Grabbing Non-integrin) (rs4804803). SP110 (rs3948464, rs1135791) is
a nuclear body multiprotein complex and has been linked to Mycobacterium tuberculosis
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resistance [34]. BTNL2 (Butyrophilin Like 2) (rs2076530) is a protein coding gene and has
been linked to sarcoidosis [35]. Initially, we assessed a total of 43 SNPs of immune-related
genes to BCG and innate immunity: TLR4, TIRAP, IFNgamma, RANTES, CCR2, MCP1
(Monocyte chemoattractant protein), IL12, P2× 7 (Purinergic receptor P2X7), VDR (Vitamin
D Receptor), which were narrowed down to the above 26 immune SNP genes based on
their significance as SNP panel signature biomarkers and literature studies.
Table 1. Genomic biomarker panel of 26 SNPs and their allelic states.




rs17215556 SLC11A1/NRAMP 2 219,258,856 0.0060 (T > C)
rs17235409 SLC11A1/NRAMP 2 219,259,732 0.0702 (G > A)
rs17235416 SLC11A1/NRAMP 2 219,259,814 0.1024 (del TGTG)
rs34448891 SLC11A1/NRAMP 2 219,246,649 MAF not reported (ins GT)
rs3731865 SLC11A1/NRAMP 2 219,250,003 0.1680 (G > C)
rs2569190 CD14 5 140,012,916 0.4734 (A > G)
rs2569193 CD14 5 140,015,495 0.2172 (G > A)
rs684 CD18 21 46,306,161 0.1639 (G > A)
rs117989670 CD18 21 46,305,913 0.0069 (A > C)
Dendritic cells
rs4804803 CD209 19 7,812,733 0.2117 (A > G)
Toll-like receptor
rs4696480 TLR2 4 154,607,126 0.4601 (T > A)
rs5743708 TLR2 4 154,626,317 0.0119 (G > A)
Inflammatory cytokines
rs1800629 TNF 6 31,543,031 0.0955 (G > A)
rs361525 TNF 6 31,543,101 0.0505 (G > A)
rs1143627 IL1B 2 113,594,387 0.4803 (C > T)
rs1143634 IL1B 2 113,590,390 0.1455 (C > T)
rs16944 IL1B 2 113,594,867 0.4651 (A > G)
rs4073 IL8 4 74,606,024 0.4972 (A > T)
rs1800896 IL10 1 206,946,897 0.3026 (A > G)
rs17860508 IL12B-near 5′ 5 158,760,200 not reported
rs1343151 IL23R 1 67,719,129 0.3237 (G > A)
Chemokines/Chemokine receptor
rs1799987 CCR5 3 46,411,935 0.4871 (A > G)
rs1801157 CXCL12 10 44,868,257 0.2080 (G > A)
Others
rs3948464 SP110 2 231,050,715 0.1028 (C > T)
rs1135791 SP110 2 231,042,276 0.3375 (T > C)
rs2076530 BTNL2 6 32,363,816 0.3779 (A > G)
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2.3. Assessment of SNP and Disease Outcome Analysis
Initially, we assessed the gene SNP panel in Stage IV MMAIT BCG+ placebo and
classified patients’ clinical outcomes into “responders” and “non-responders” based on
their gene SNP scores. The gene panel score was calculated as described in the Materials and
Methods section for each patient. This data was then plotted using Principal Component
Analysis (PCA). The variability of the data points is shown on the plotted data in principal
component 1 and 2 (Figure 4A). A cut-off point of 0.005 at component 2 was selected
to separate responders from non-responders. The distribution of principal component 2
among all patients is shown in a histogram (Figure 4B), wherein the cut-off point selected
was based on the separation of the data distributed by principal component 2. The allele
used for calculation of the co-efficient for each SNP was determined by PCA and is indicated
in Figure 4C.
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(A) The gene SNP panel score for each patient is represented as a data point on principal component 1 and 2, representing
the majority of the data variability. Red line = cut-off point at 0.005. (B) Histograms showing the distribution of principal
component 2 among all patients. A cut-off point at component 2 was selected to dichotomize the patients into two groups,
termed here as responders and non-responders. (Responders: Comp2 ≤ 0.005; Non-responders: Comp2 > 0.005) The cut-off
point was selected at the point of separation in the data distribution. (C) The co-efficient for each gene SNP was determined
by PCA. The alleles used for calculation of the co-efficient are indicated.
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To further explore the findings, an additional PCA was performed in the same cohort
of Stage IV MMAIT BCG+ placebo patients. Plotting principal components 1 and 2 revealed
a separation between responders and non-responders (Figure S1A). The said cut-off of
0.005 is shown to dichotomize the patients into responders and non-responders in principal
component 1. The distribution of principal component 1 among the 92 patients is shown
in a histogram along with the cut-off of 0.005 as a threshold to separate the two groups
(Figure S1B). Correspondingly, Figure S1C reports the principal component 1 coefficient for
each SNP found by the PCA.
A Kaplan–Meier survival curve revealed a significant difference in DFS between
responders and non-responders in the stage IV pilot cohort (p = 0.02) but no significant dif-
ference in OS was observed (Figure 5A). This was anticipated, as OS in Stage IV is typically
short and less variable in advanced stage metastatic melanoma patients. As defined by
the SNP panel analysis, patients in the responder group had a median DFS of 18.7 months
compared to 9.4 months in the non-responder group. There was a trend observed towards
an improved OS in the responder group when compared to the non-responder group, al-
though statistical significance was not reached (Figure 5A). In multivariable Cox regression
analysis, the biomarker panel SNP score was the only significant predictor of DFS with a
hazard ratio (HR) of 1.84 (95% CI 1.09–3.13, p = 0.021) (Table 2). There were no significant
associations between the SNP panel and patient clinicopathologic variables in this pilot
cohort study. This pilot study demonstrated that the SNP panel score correlates to the DFS
outcome only.
Table 2. Multivariable stepwise Cox regression analysis of disease outcome: biomarker SNP panel
and clinicopathologic characteristics in the discovery cohort of MMAIT stage IV BCG-treated patients.
Variable
Disease-Free Survival Overall Survival
Multivariable Analysis Multivariable Analysis
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Table 2. Cont.
Variable
Disease-Free Survival Overall Survival
Multivariable Analysis Multivariable Analysis























* Variables that do not have a p-value shown were not significant. Bold font indicates p value ≤ 0.05.
The SNP panel algorithm derived from the pilot cohort was then applied to the stage
III MMAIT verification patient cohort. There were no significant associations between the
SNP panel and patient clinicopathologic variables in the verification cohort. However, the
SNP panel was able to classify the patients into responders versus non-responders with a
significant difference observed in OS (p = 0.049), having a 75% survival rate at 46.3 months
for responders versus 29.4 months for non-responders but no significant difference was
observed in DFS between responders and non-responders (Figure 5B). The biomarker panel
SNP score was also an independent predictor of OS (HR 1.67, 95% CI 1.07–2.67, p = 0.025)
in multivariable Cox regression analysis (Table 3).
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patients (n = 269), responders had an improved OS (p = 0.049). DFS = disease-free survival, OS = overall survival, M AIT =
Malignant Melanoma Active Immunotherapy Trial. * p < 0.05.
To confirm the predictive ability of a SNP panel to determine responders and non-
responders to adjuvant BCG immunotherapy in melanoma patients, we assessed a control
patient group of 80 AJCC stage III non-BCG or non-immunotherapy treated patients from
our MSLT-I clinical trial [36–38]. We hypothesized that the immune SNP panel would not
be an effective classification tool for patient outcome in this control patient cohort. The
algorithm and classification method derived from the verification patient cohort was then
applied to the stage III control cohort patients. There were no significant differences in
DFS (p = 0.64) or OS (p = 0.93) in this control patient group, suggesting that the gene SNP
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panel applies to BCG immunotherapy responses and not to melanoma patients that are not
receiving BCG therapy.
Table 3. Multivariable stepwise Cox regression analysis of survival: biomarker SNP panel and
clinicopathologic characteristics in the validation cohort of MMAIT stage III BCG-treated patients.
Variable
Disease-Free Survival Overall Survival
Multivariate Analysis Multivariate Analysis






0.158 1.31 (0.90–1.93) 0.025 1.67 (1.07–2.67)
Age 0.007 1.02 (1.01–1.03)




1.01–2.00 mm 0.71 (0.40–1.30)
2.01–4.00 mm 0.59 (0.32–1.11)
>4.00 mm 0.98 (0.52–1.85)
Unknown 0.55 (0.29–1.04)
Lymph Node Positive 0.048
1 1.00(Reference)














Yes 0.061 1.60 (0.98–2.63) 0.008 2.08 (1.21–3.65)
Unknown 1.02 (0.64–1.65) 1.13 (0.65–2.00)
* Variables that do not have a p-value shown were not significant. Bold font indicates p value ≤ 0.05.
2.4. BCG Treated Immune SNP Panel Correlation to Patients’ DTH Response to PPD
In the MMAIT stage III multicenter clinical trial, patients (n = 269) were assessed
for delayed type hypersensitivity (DTH) responses to determine their level of immune
activation by BCG vaccination. To measure DTH responses, the purified protein derivative
(PPD) skin test [26] was assessed on MMAIT clinical trial patients. PPD skin test response
Cancers 2021, 13, 91 13 of 23
is used to assess the BCG innate immune activity in patients [39]. The level of DTH to
PPDs quantification is described in the Materials and Methods section [39]. The analysis
demonstrated a significant correlation between specific gene SNPs and DTH-PPD responses
in BCG treated melanoma patients. The significantly correlated gene SNPs were: rs1143627
(IL1β), rs17215556 NRAMP1/SLC11A1, rs16944 (IL-1β) and rs1801157 (CXCL12) with
p values of: p = 0.003, p = 0.029, p = 0.001, and p = 0.050, respectively (Table 4).
Table 4. BCG treated MMAIT stage III melanoma patient cutaneous DTH response to PPD correlation
to immune gene SNP panel.





All other gene SNPs did not significantly correlate to DTH-PPD response. p value was assessed by performing
the likelihood ratio chi-square test (n = 269 patients).
3. Discussion
The development of a predictive immune response biomarker to identify patients
as potentially responsive or non-responsive to adjuvant immunotherapy is important for
optimizing and triaging treatments for patients. The elucidation of factors for a patient’s
clinical response to immune agents will allow for better selection of therapies with the
greatest potential for success while minimizing the risks of ineffective therapies. Patients’
immunity is heterogeneous due to inherited genetic changes such as SNPs from specific key
immune related genes. This is a critical problem in assessing human cancer immunotherapy
responses. In mouse models, this inherited immune heterogeneity in treatment respon-
siveness is not as prevalent due to the genetic clonality of the inbred mouse models. In
humans, inherited and innate immunity heterogeneity is quite significant and poorly un-
derstood in relation to patients’ cancer immunotherapy responses. Clinical studies focus
on the immunotherapy agents’ direct efficacy and toxicity and not the hosts’ inherited
immune system. Therefore, understanding the functional SNPs of specific genes during
immunotherapy would be a beneficial predictive immunologic biomarker for a clinician to
help select specific immunotherapies. This information could be used in addition to other
known clinical factors in decision making. Our study demonstrates an essential neglected
immune biomarker approach that can provide a new layer of importance in personalized
cancer immunotherapy rationale to improve patient outcomes and treatment regimen
decision making. Patients not likely to generate effective specific immune related responses
due to inherited changes of specific cytokines/receptors, chemokines/receptors, and/or
immune cell marker genes may not have a robust immune response to immunotherapies.
Thus, alternative non-immunological based therapies may be more appropriate. This strat-
egy can be applied to the usage of the modern day immunotherapies such as checkpoint
inhibitor immunotherapies versus targeted therapies such as BRAF/MEK inhibitors for
melanoma patients before treatment [1].
To address the issue of prospectively identifying patients that will respond to treat-
ment from non-responders, we selected gene SNPs that represent a range of key immune
pathways relevant to the activation of the BCG host innate immune system and melanoma
anti-tumor immunity. Macrophages/monocytes play a key role in trained innate immunity,
particularly in BCG responses, whereby they engulf the pathogen and stimulate lympho-
cytes and host immune responses [27]. These immune cells have also been implicated in
controlling tumor growth and progression through tumor infiltration and promotion of
inflammation. The release of these inflammatory molecules such as tumor necrosis factor
(TNF) and specific cytokines can help mediate tumor apoptosis and control tumor cell prolif-
eration [40]. In addition, macrophages/monocytes produce multiple pro-angiogenic factors,
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such as vascular endothelial factor (VEGF), granulocyte macrophage colony-stimulating
factor (GM-CSF), IL-1, and IL-6, all of which are known to have significant effects on
cancer cells [40]. BCG immunization is known to activate macrophage/monocytes in both
cancer and non-cancer patients [13,27]. Specifically, NRAMP1 is expressed by macrophages
and mediates innate resistance to the host infection by several pathogens, including BCG
Mycobacterium [41–43]. We included several SNPs in the NRAMP1 gene that are reportedly
associated with susceptibility to TB (tuberculosis) [44], autoimmune diseases [45], and a
response to BCG therapy in patients with superficial bladder cancer [46]. In intravesical
treatment of bladder cancer, BCG triggers a massive release of multiple types of cytokines
and recruits immune cells, its therapeutic effect is associated with the induction of T helper
type 1 and 2 (Th1/2) responses [13]. BCG is still considered an effective treatment for early
stage bladder cancer [47], which implies that the activation of innate immune responses is
effective in controlling cancer progression.
We also selected IL-1β for it is associated with enhanced trained innate immunity [48].
IL-1β is a pro-inflammatory cytokine, which is expressed by various immune cells including
macrophages, and is known to play a critical role in innate host defense and helps stimulate
the production of other inflammatory cytokines such as IL-8, IL-6, TNF-α, etc. [49,50].
Polymorphisms in inflammatory cytokines (TNF, IL-1β, IL-8, IL-10, IL-12β, and IL-23R)
have been associated with TB and several inflammatory diseases [51–54]. IL-10 is associated
with limiting resistance to infection against M. tuberculosis [55] and inhibiting Th1 immune
response [56]. Dendritic cells are important antigen-presenting cells that, once activated,
can present tumor-related antigens coordinating immune responses. DC-SIGN (dendritic
cell-specific ICAM-3 grabbing non-integrin; CD209) is expressed on dendritic cells and
functions in cell adhesion, pathogen recognition [57,58], and the uptake of a variety of
pathogens including Mycobacterium tuberculosis [59].
TLRs are membrane receptors expressed by macrophages, T cells, and dendritic
cells. SNPs in TLRs have been reported to confer susceptibility to various infectious and
inflammatory diseases [60], including TB [61]. TLRs on immune and tumor cells have
recently been shown to play an important role in the activation of immunotherapy [62].
TLR2 was selected due to its protective role and critical involvement in innate immune
responses against mycobacteria [63,64].
Chemokines and chemokine receptors are known to regulate the phenotypic environ-
ment of tumors by influencing immune cell infiltration, tumor angiogenesis and survival,
hence playing a critical role in tumor progression and therapeutic outcomes [65]. CCR5
and CXCL12 were selected due to their role in immune-response pathways in cancer
patients [66,67]. Chemokine receptor CXCR4 and its ligand CXCL12 play an important
homeostatic role in the homing and activation of macrophage lineage cell responses during
infection and activating immune cells in tumor immune responses [68]. CCR5 polymor-
phisms have been shown to be associated with the survival of melanoma patients receiving
immunotherapy [66,69]. CCR5 ligands are MIP (macrophage inflammation protein) α,β
which attracts T cells. In contrast, CXCL12 is associated with tumor initiation and progres-
sion [67] and is involved in the recruitment of plasmacytoid dendritic cells (pDCs) [65].
SP110 is involved in the regulation of gene transcription. This protein has been re-
ported to be linked to Mycobacterium tuberculosis resistance [34] and may influence cell
apoptosis, differentiation and activation [70,71]. Several SP110 SNPs were found in popu-
lations with TB from West Africa, China, and India [70]. Lastly, BTNL2, which encodes a
major histocompatibility complex, class II associated type I transmembrane protein belongs
to the butyrophilin-like B7 family of immunoregulators. It is associated with decreased
bacterial burden [72] and the downregulation of T cell activation [73,74].
DTH responses using the PPD test is a standard approach to measure BCG recall
responses. DTH measures cell-mediated responses and the recruitment, activation, and
stimulation of macrophages/monocytes, and T-cells to the site of challenging antigen injec-
tion. In a previous study, Faries et al. [26] showed that a positive DTH skin test is associated
with increased survival in melanoma patients. In this study, we observed a significant
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correlation (p ≤ 0.05) between the DTH-PPD responses in BCG treated melanoma patients
and the four gene SNPs from our panel: IL1β, NRAMP1/SLC11A1, and CXCL12. Involve-
ment in the recruitment of immune cells, chemokines, and cytokines to the DTH challenge
site are all important for a positive DTH-PPD response. Macrophages and IL-1β secretion
are known to be involved in the DTH responses [75,76]. CXCL12 is a chemokine that
attracts CXCR4+ immune cells, such as macrophage/monocytes, T cells, and pDCs [65,68].
This demonstrated an in vivo functional relation of DTH related to BCG recall immunity
involving specific immune SNP genes.
Using the established SNP gene coefficient formula and cut-off point initially derived
from more advanced melanoma patients (MMAIT Stage IV, pilot cohort), we developed
a 26 gene panel. We then applied this panel to stage III MMAIT multicenter clinical trial
melanoma patients who benefited from BCG treatment with an improved disease outcome.
The use of gene SNPs potentially allows for the identification of patients rendered disease-
free who will likely have a poor disease outcome. This suggests patients who had sub-
clinical systemic disease can have effective tumor immune control through innate immune
system priming, by BCG. We have verified a novel gene panel of 26 SNPs effectiveness in
predicting disease outcome after adjuvant BCG therapy. This SNP panel requires further
verification in a larger adjuvant clinical trial. It is interesting that BCG treatment is effective
in early-stage melanoma patients with a subclinical tumor burden very similar in its
effectiveness to treating early-stage bladder cancer.
This panel may be applied to other immunotherapies in melanoma patients. New
gene SNPs can be developed to address modern immunotherapy agents such as anti-
CTLA-4, PDL-1,PD-1, and cancer vaccines. It is inevitable that individual immunotherapies
activating specific types of immune responses can have different gene SNPs. If subsequent
validation studies are successful, the SNP panel may be included as an important tool,
useful prior to the selection of immunotherapy for patients.
Previous studies reported that BCG provides protection against multiple microorgan-
isms such as bacteria (S. aureus), fungi (C. albicans), and viruses (yellow fever virus) [77].
Moreover, a recent clinical trial of BCG vaccination showed that it can protect the elderly
against respiratory tract infections [78]. Innate immune cells can be “primed” by BCG,
which is known as trained innate immunity that can be effective against pathogen infec-
tions and early stage tumors [79]. It is also said to be involved in the transcriptional and
epigenetic rewiring of innate immune cells (e.g., myeloid and NK cells), which leads to an
increase in cytokine production and an enhanced killing capacity [27,78,80]. Additionally,
BCG can provide a long-lasting change in the immune system specifically in heterologous T
helper 1 (Th1) and Th17 immune responses in innate trained immunity [81]. With the ongo-
ing COVID-19 pandemic, there have been reports that patients who are BCG-vaccinated are
less susceptible to serious illness and have less severe COVID-19 symptoms [82]. Several
studies are currently being conducted worldwide to determine whether BCG vaccination
has a protective effect against COVID-19 (clinicaltrials.gov#–NCT04537663, NCT04379336,
NCT04369794, NCT04461379, NCT04347876) [82–85]. These studies indicate that the im-
munologic SNP panel could also be utilized as an important tool if BCG is preventative or
can reduce the pathogenicity of COVID-19 as well as other infectious diseases.
4. Materials and Methods
4.1. Melanoma Patients
This study involved AJCC stage III and IV melanoma patients from the multicenter
phase III clinical trials. These patients were divided into 3 cohorts: pilot, verification,
and control. All patients were entered into the multicenter phase III clinical trials, had
undergone complete surgical resection and were rendered free of primary and metastatic
disease [16,17]. Post-operative computed tomography (CT) of the chest, abdomen, and
pelvis, and magnetic resonance imaging (MRI) or CT of the brain was used to confirm
no evidence of disease prior to the initiation of adjuvant therapy or follow-up without
treatment. Patients in the pilot Stage IV patients (n = 92) and verification Stage III patient
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(n = 269) cohorts were randomized to receive BCG adjuvant immunotherapy after being
rendered disease-free by surgery, and were enrolled in the phase III international Malignant
Melanoma Active Immunotherapy Trials (MMAIT) Stage IV and Stage III, respectively,
sponsored by JWCI trial center [see references for complete details of the trials] [16,17,26].
Patients in the control cohort did not receive BCG or any form of immunotherapy and
were enrolled in the phase III international study, Multicenter Selective Lymphadenectomy
Trial (MSLT-I). MSLT-I patients assessed in this control cohort were SLN (+) and received
complete lymph node dissection to be rendered disease-free status [36–38,86].
The MMAIT studies were two phase III randomized double-blind international multi-
center trials comparing BCG plus a melanoma cell vaccine (CanVaxinTM) versus BCG plus
placebo after complete surgical resection rendering patients disease-free in AJCC stage III
and IV melanoma patients (clinicaltrials.gov# NCT00052130, stage III study; #NCT00052156,
stage IV study) (Figure 1 CONSORT diagram) [16,17,26]. Only the BCG treatment plus
placebo arm was assessed. The placebo given was RPMI-1640 containing 7.5% human
serum albumin and 10% dimethyl sulfoxide. The studies enrolled participants between
May 1998 and March 2005, with study follow-up until May 2010 (Figures 1 and 2). Eligible
participants were patients 18–80 years of age, with histologically confirmed metastatic
melanoma (AJCC stage III or IV), clinically disease-free after complete lymphadenectomy
or metastasectomy, and Eastern Cooperative Oncology Group (ECOG) performance status
of 0 or 1. There were 1656 patients (1160 AJCC stage III patients and 496 AJCC stage IV
patients) enrolled in the MMAIT studies. BCG (Tice strain; Organon Technika, Durham,
NC, USA) was used as an adjuvant immunotherapy. CanVaxinTM is an allogeneic whole-
melanoma cell vaccine (3 irradiated characterized melanoma cell lines) [87]. Following
randomization and within 90 days of complete surgical resection rendering them disease-
free, participants were treated with BCG at days 0 and 14. BCG doses were 3 × 106 colony
forming units (CFU) on day 0 and 1.5 × 106 CFU on day 14. Patients in the BCG plus
CanVaxinTM group received CanVaxinTM at days 0, 14, 28, 42, 56, and then monthly there-
after during year 1, every 2 months in year 2, and every 3 months in years 3–5 (Figure 2).
Participants in the BCG plus placebo group received injections at these same time periods.
BCG was administered intradermally in the axilla or groin area on days 0 and 14. Patient
peripheral blood leukocytes (PBLs) were procured from heparinized blood drawn before
BCG treatment, processed and cryopreserved at −80 ◦C in DMSO medium as previously
described [17]. The Institutional Review Board (IRB) at JWCI/Saint John’s Health Center
and all participating clinical trial sites have approved the clinical trial and companion
biomarker study [17]. This study followed the principles in the Declaration of Helsinki. All
participants provided IRB approved informed written consent.
Patients in the control cohort (no BCG or other immunotherapy treatment) were en-
rolled from the MSLT-I clinical trial (clinicaltrials.gov# NCT00275496) (Figure 1 CONSORT
diagram) [36,37]. MSLT-I is a phase III international multicenter clinical trial that random-
ized melanoma patients with invasive primary melanoma with no clinical evidence of
lymph node metastasis. Patients underwent wide skin excision and SLN biopsy, followed
by complete lymphadenectomy for resection of potential metastases versus wide excision
and regional draining nodal observation with subsequent lymphadenectomy for nodal
recurrence during observation. Patients in MSLT-1 were enrolled between 20 January 1994
and 29 March 2002 (10-year follow-up available for MSLT-I). Patients used in the MSLT-I
trial had pathology defined metastasis and were classified as AJCC Stage III.
4.2. DTH-PPD Test
Delayed type hypersensitivity (DTH) to specific antigens is widely used as a measure
of host immune competence [39]. DTH to BCG was assessed by the purified protein
derivative (PPD) test in the MMAIT-III patients prior to the first injection of BCG plus
placebo and at day 28, day 56, and month 4, or until positive. This standard assay is
commonly used in an in vivo skin test to determine levels of response to BCG by applying
an intradermal injection of tuberculin (PPD) to a patient’s forearm and then reading the
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reaction between 48–72 h after administration [26]. After 48 h, DTH responses were
assessed and measured in mm, and a positive cut-off at ≥7 mm was applied [39]. The
largest DTH response within 4 months after the patient entered the trial was used for
analysis [39].
4.3. Peripheral Blood Leukocytes (PBLs) Collection
Peripheral blood was processed for leukocytes and cryopreserved in liquid nitrogen
as previously described [17]. Due to logistics, processing for PBL specimens was carried
out at U.S. cancer center sites only. Thus, only patients in the BCG plus placebo group from
U.S. centers were enrolled in the MMAIT studies. Results in the pilot cohort of patients
with stage IV melanoma in the MMAIT-IV study were verified using the verification cohort
of patients with AJCC stage III melanoma who were selected from the MMAIT-III study.
PBLs were collected prior to surgery similar to the MSLT-I trial.
4.4. Experimental Approach
Candidate SNPs were identified by a literature review of genetic polymorphisms asso-
ciated with macrophage cytokines or monocyte-related immune response pathways to BCG
and/or TB. The final biomarker panel in this study consisted of 26 SNPs as presented in
Table 1 and can be broadly grouped into immune related genes: macrophages/monocytes
(NRAMP1/SLC11A1, CD14, CD18); dendritic cells (CD209/DC-SIGN); TLR (TLR2); in-
flammatory cytokines (TNF, IL1β, IL8, IL10, IL12β, and IL23R); and chemokine/chemokine
receptors (CCR5, CXCL12).
For the pilot, verification, and control patient cohorts, we extracted DNA from cry-
opreserved PBLs by QIAamp DNA mini kit (QIAGEN, Valencia, CA, USA) as previously
described [88]. For the control cohort, DNA was extracted from Flinders Technology
Associates (FTA) cards (VWR International, Radnor, PA, USA), which were spotted with
whole blood using the GenSolve kit (GenVault, Carlsbad, CA, USA). DNA was quantified
using the Quant-iT PicoGreen dsDNA assay kit (Invitrogen, Carlsbad, CA, USA) as pre-
viously described [89]. DNA was characterized for the candidate SNPs by MassARRAY
MALDI-TOF Mass Spectrometry (Sequenom, San Diego, CA, USA) [89]. PCR and iPLEX
(extension) primers were designed by using SEQUENOM database. Data analysis was
performed with MassARRAY Typer 4.0.20 software, as previously described [90]. If peaks
of the specific gene SNP were not well defined, they were repeated until clear. If clarity
was not significant, the patient sample data was not used.
4.5. Biostatistical Analysis
The primary endpoints were overall survival (OS) and disease-free survival (DFS).
OS was defined as time to death or censored if alive at the time of the last follow-up in
2010. DFS was defined as the time to melanoma recurrence, death, or censored if without
melanoma recurrence at the date of the last follow-up. Survival time was calculated from
the date of randomization to the date of event (death or melanoma recurrence) or the last
follow-up.
We chose to analyze the genotype data by Principal Component Analysis (PCA) [91].
This method has been used commonly for visualization and analysis of high dimensional
data characteristic of multi-gene genomic studies. The large number of SNPs evaluated
allowed us to avoid using models that fit parameters to outcome (e.g., proportional hazards
models) overfitting.
The allele status of the 26 SNPs was determined for each patient as described in the
experimental approach. We considered the chromosomal status (i.e., common homozygotes,
heterozygotes, and rare homozygotes) at each SNP as continuous variables, assigning one
point for each allele [92]. For example, for a SNP with an allele “A”, if the patient’s genotype
for that SNP was “AA” then 2 is assigned; the value is 1 if the genotype is AG; and if
the genotype is GG then the value is 0. This was carried out for all 26 SNPs, and PCA
was conducted to determine the coefficient for each SNP. Principal component 2 (PC2)
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was the first to show a dichotomized distribution. PC2 will be referred to as the patient’s
“SNP score”, which is calculated using PC2 = P1X1 + P2X2 + . . . + P27X27, where Pi is the
principal component 2 coefficient for each SNP as generated by the PCA algorithm, while
Xi is each individual SNP’s allelic state as a value of 0, 1, or 2, which is determined as
outlined above. From our PCA data, a cut-off of 0.005 was selected from the mean (and by
visual inspection) of component 2 from 92 patients in the pilot cohort (MMAIT stage IV
BCG-treated patients), and they were separated into two groups, termed here as responsive
(Comp2 ≤ 0.005) and non-responsive (Comp2 > 0.005) to adjuvant BCG therapy.
We hypothesized that patients at later stages of disease would acquire mutations and
prognostic markers correlating with poor disease outcome. These markers could then be
applied to earlier stages of the disease to predict patients’ outcome at an earlier stage. PCA
was applied to the pilot cohort from whom a SNP coefficient formula and cut-off point
were derived (Figure 4). The same SNP coefficient formula and cut-off point were then
applied to the verification and control cohorts.
Associations between SNP status and clinicopathologic factors were assessed by
Pearson’s correlation coefficient for continuous variables and Student’s T-test or ANOVA
for categorical variables. We analyzed survival by the Kaplan-Meier method. Multivariable
survival analyses by stepwise Cox proportional hazards analysis were carried out using
known prognostic covariates (i.e., age, sex, Breslow thickness, site of primary lesion,
ulceration, and number of positive lymph nodes). All p-values were two-sided and p ≤ 0.05
was considered statistically significant. All statistical analyses were performed with JMP®,
Version 9.0 (SAS Institute, Inc., Cary, NC, USA). The significant correlation between the
SNP panel to DTH-PPD responses in BCG treated melanoma patients was assessed by
performing the likelihood ratio and Chi-Square test.
5. Conclusions
This study is the first immune SNP-based predictive multi-biomarker test for adju-
vant BCG immunotherapy in AJCC stage III and IV metastatic melanoma patients in a
multicenter clinical trial setting. In this study, we successfully determined the allelic status
of the 26 SNPs for each patient in all three melanoma cohorts (AJCC stage III, stage IV,
and control Stage III) and categorized them into two outcome groups: responders and
non-responders to adjuvant BCG therapy. As a result, by using the 26 SNP panel we
were able to demonstrate that responders to adjuvant BCG therapy showed a significant
improvement in DFS in the pilot cohort of stage IV melanoma patients and OS in the
verification cohort of stage III melanoma patients.
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